Arena Pharmaceuticals, Inc. (ARNA): Price and Financial Metrics
GET POWR RATINGS... FREE!
ARNA POWR Grades
- Growth is the dimension where ARNA ranks best; there it ranks ahead of 54.05% of US stocks.
- The strongest trend for ARNA is in Quality, which has been heading down over the past 26 weeks.
- ARNA's current lowest rank is in the Sentiment metric (where it is better than 2.75% of US stocks).
ARNA Stock Summary
- The capital turnover (annual revenue relative to shareholder's equity) for ARNA is 0 -- better than only 5.95% of US stocks.
- With a price/sales ratio of 106,899.1, Arena Pharmaceuticals Inc has a higher such ratio than 99.98% of stocks in our set.
- Revenue growth over the past 12 months for Arena Pharmaceuticals Inc comes in at -83.07%, a number that bests just 1.59% of the US stocks we're tracking.
- Stocks with similar financial metrics, market capitalization, and price volatility to Arena Pharmaceuticals Inc are SVRA, BLU, FSR, NYMX, and URG.
- Visit ARNA's SEC page to see the company's official filings. To visit the company's web site, go to www.arenapharm.com.
ARNA Valuation Summary
- ARNA's price/sales ratio is 56703.5; this is 499490.31% higher than that of the median Healthcare stock.
- ARNA's price/earnings ratio has moved up 126.3 over the prior 243 months.
- ARNA's price/earnings ratio has moved up 126.3 over the prior 243 months.
Below are key valuation metrics over time for ARNA.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| ARNA | 2021-08-31 | 56703.5 | 3.3 | -6.7 | -5.8 |
| ARNA | 2021-08-30 | 55449.1 | 3.3 | -6.5 | -5.6 |
| ARNA | 2021-08-27 | 56177.2 | 3.3 | -6.6 | -5.7 |
| ARNA | 2021-08-26 | 54387.7 | 3.2 | -6.4 | -5.5 |
| ARNA | 2021-08-25 | 54710.5 | 3.2 | -6.4 | -5.5 |
| ARNA | 2021-08-24 | 54207.0 | 3.2 | -6.4 | -5.5 |
ARNA Growth Metrics
- Its 5 year price growth rate is now at 215.51%.
- Its 3 year net cashflow from operations growth rate is now at 785.43%.
- Its 2 year cash and equivalents growth rate is now at -63.11%.
The table below shows ARNA's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2021-12-31 | 0.054 | -452.016 | -616.433 |
| 2021-09-30 | 0.037 | -437.903 | -582.985 |
| 2021-06-30 | 0.057 | -395.123 | -484.111 |
| 2021-03-31 | 0.057 | -379.038 | -422.944 |
| 2020-12-31 | 0.319 | -353.094 | -404.734 |
| 2020-09-30 | 3.284 | -308.139 | -370.884 |
ARNA's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- ARNA has a Quality Grade of C, ranking ahead of 63.92% of graded US stocks.
- ARNA's asset turnover comes in at 0 -- ranking 440th of 680 Pharmaceutical Products stocks.
- MRSN, CRBP, and ARWR are the stocks whose asset turnover ratios are most correlated with ARNA.
The table below shows ARNA's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.000 | 1 | -0.626 |
| 2021-03-31 | 0.000 | 1 | -0.505 |
| 2020-12-31 | 0.000 | 1 | -0.462 |
| 2020-09-30 | 0.003 | 1 | -0.425 |
| 2020-06-30 | 0.004 | 1 | -0.368 |
| 2020-03-31 | 0.005 | 1 | -0.316 |
ARNA Price Target
For more insight on analysts targets of ARNA, see our ARNA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $95.25 | Average Broker Recommendation | 1.34 (Strong Buy) |
ARNA Stock Price Chart Interactive Chart >
ARNA Price/Volume Stats
| Current price | $99.99 | 52-week high | $100.00 |
| Prev. close | $99.93 | 52-week low | $45.50 |
| Day low | $99.97 | Volume | 5,718,500 |
| Day high | $100.00 | Avg. volume | 1,561,326 |
| 50-day MA | $93.21 | Dividend yield | N/A |
| 200-day MA | $70.04 | Market Cap | 6.17B |
Arena Pharmaceuticals, Inc. (ARNA) Company Bio
Arena Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing drugs to address unmet medical needs. The company was founded in 1997 and is based in San Diego, California.
Latest ARNA News From Around the Web
Below are the latest news stories about Arena Pharmaceuticals Inc that investors may wish to consider to help them evaluate ARNA as an investment opportunity.
Arena Pharmaceuticals GAAP EPS of -$2.54 misses by $0.31Arena Pharmaceuticals press release (NASDAQ:ARNA): Q4 GAAP EPS of -$2.54 misses by $0.31. Cash, cash equivalents and marketable securities were $0.7B at December 31, 2021 as compared to $1.1B at December 31, 2020... |
Arena Reports Fourth Quarter and Full Year 2021 Financial Results and Key Program UpdatesPARK CITY, Utah, February 23, 2022--Arena Pharmaceuticals today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2021 |
SFO opens criminal probe into collapse of Arena TelevisionThe Serious Fraud Office has opened a criminal investigation into Arena Television, a collapsed broadcaster that worked on the Euro 2020 football tournament and Glastonbury. |
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PARK CITY, Utah, February 17, 2022--Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the Compensation Committee of its Board of Directors granted to 18 new employees 18,527 inducement restricted stock units ("RSUs"). The inducement RSUs have a grant date and vesting commencement date of February 15, 2022 and were granted as inducements material to the new employees entering employment with Arena in accordance with Nasdaq Listing Rule 5635(c)(4). |
Top Merger Stocks Held By Fund Managers, Mid-Q1 2022Each quarter, I spend some time reading Form 13F filings from hedge funds that specialize in merger arbitrage, documenting, and then analyzing which M&A stocks the funds have bought and which ones they haven't. I then compile the top 10 stocks held in these funds and share the results with... |
ARNA Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | 7.59% |
| 1-year | 40.36% |
| 3-year | 64.76% |
| 5-year | 492.71% |
| YTD | 7.59% |
| 2021 | 20.97% |
| 2020 | 69.15% |
| 2019 | 16.61% |
| 2018 | 14.66% |
| 2017 | 139.23% |
Continue Researching ARNA
Want to see what other sources are saying about Arena Pharmaceuticals Inc's financials and stock price? Try the links below:Arena Pharmaceuticals Inc (ARNA) Stock Price | Nasdaq
Arena Pharmaceuticals Inc (ARNA) Stock Quote, History and News - Yahoo Finance
Arena Pharmaceuticals Inc (ARNA) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...